PL3575293T3 - Sól etanosulfonianowa n-{5-[(6,7-dimetoksy-4-chinolinyl)oksy]- 2-pirydy-nylo}-2,5-diokso-1-fenylo-1,2,5,6,7,8-heksahydro-3-chinolinokarboksamidu - Google Patents

Sól etanosulfonianowa n-{5-[(6,7-dimetoksy-4-chinolinyl)oksy]- 2-pirydy-nylo}-2,5-diokso-1-fenylo-1,2,5,6,7,8-heksahydro-3-chinolinokarboksamidu

Info

Publication number
PL3575293T3
PL3575293T3 PL18744970T PL18744970T PL3575293T3 PL 3575293 T3 PL3575293 T3 PL 3575293T3 PL 18744970 T PL18744970 T PL 18744970T PL 18744970 T PL18744970 T PL 18744970T PL 3575293 T3 PL3575293 T3 PL 3575293T3
Authority
PL
Poland
Prior art keywords
quinolinecarboxamide
hexahydro
dioxo
quinolinyl
pyridinyl
Prior art date
Application number
PL18744970T
Other languages
English (en)
Inventor
Takahiro Nekado
Hideomi KIJIMA
Shizuka Ono
Toshihiko Nishiyama
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Publication of PL3575293T3 publication Critical patent/PL3575293T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18744970T 2017-01-26 2018-01-25 Sól etanosulfonianowa n-{5-[(6,7-dimetoksy-4-chinolinyl)oksy]- 2-pirydy-nylo}-2,5-diokso-1-fenylo-1,2,5,6,7,8-heksahydro-3-chinolinokarboksamidu PL3575293T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017011835 2017-01-26
PCT/JP2018/002250 WO2018139527A1 (ja) 2017-01-26 2018-01-25 キノリン誘導体のエタンスルホン酸塩
EP18744970.7A EP3575293B1 (en) 2017-01-26 2018-01-25 Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide

Publications (1)

Publication Number Publication Date
PL3575293T3 true PL3575293T3 (pl) 2021-09-06

Family

ID=62979439

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18744970T PL3575293T3 (pl) 2017-01-26 2018-01-25 Sól etanosulfonianowa n-{5-[(6,7-dimetoksy-4-chinolinyl)oksy]- 2-pirydy-nylo}-2,5-diokso-1-fenylo-1,2,5,6,7,8-heksahydro-3-chinolinokarboksamidu

Country Status (21)

Country Link
US (1) US10836747B2 (pl)
EP (1) EP3575293B1 (pl)
JP (1) JP6605763B2 (pl)
KR (1) KR102571911B1 (pl)
CN (1) CN110225908A (pl)
AU (1) AU2018211801B2 (pl)
BR (1) BR112019015352A2 (pl)
CA (1) CA3051605A1 (pl)
DK (1) DK3575293T3 (pl)
ES (1) ES2872923T3 (pl)
HU (1) HUE054883T2 (pl)
IL (1) IL268221B (pl)
MX (1) MX2019008787A (pl)
MY (1) MY196680A (pl)
PH (1) PH12019501693A1 (pl)
PL (1) PL3575293T3 (pl)
PT (1) PT3575293T (pl)
RU (1) RU2019123279A (pl)
SG (1) SG11201906819VA (pl)
TW (1) TWI779007B (pl)
WO (1) WO2018139527A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3673907A4 (en) * 2017-08-23 2020-08-19 ONO Pharmaceutical Co., Ltd. CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
CN117624128A (zh) * 2022-08-30 2024-03-01 药捷安康(南京)科技股份有限公司 喹啉衍生物抑制剂的晶型及其制备方法及用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428234B1 (en) * 2000-01-07 2002-08-06 Closure Medical Corporation Adhesive applicator tips with improved flow properties
JP2003519698A (ja) 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ,インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
WO2008048375A1 (en) 2006-05-19 2008-04-24 Bayer Healthcare Ag Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
CA2655128A1 (en) 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
RU2010146474A (ru) 2008-04-16 2012-05-27 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. (De) Производные хинолина в качестве ингибиторов axl киназ
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CA2723617A1 (en) 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
EP2349328A1 (en) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Methods for the treatment of cancer
JP2010178651A (ja) 2009-02-04 2010-08-19 Eisai R & D Management Co Ltd Hgfr阻害物質の作用検定方法
JP5525612B2 (ja) 2010-07-23 2014-06-18 国立大学法人 東京大学 含窒素複素環誘導体
JP5791412B2 (ja) 2010-07-26 2015-10-07 日本碍子株式会社 セラミックヒーター
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
ES2553610T3 (es) 2010-12-14 2015-12-10 Electrophoretics Limited Inhibidores de la caseína cinasa 1 delta (CK1delta)
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
JP2013074633A (ja) 2011-09-26 2013-04-22 Oki Electric Ind Co Ltd スイッチング電源装置及び現金自動預け払い装置
EP3045453A1 (en) 2011-11-14 2016-07-20 Cephalon, Inc. Uracil derivatives as axl and c-met kinase inhibitors
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物

Also Published As

Publication number Publication date
EP3575293A1 (en) 2019-12-04
AU2018211801A1 (en) 2019-08-15
CN110225908A (zh) 2019-09-10
RU2019123279A (ru) 2021-02-26
IL268221B (en) 2022-03-01
US10836747B2 (en) 2020-11-17
PT3575293T (pt) 2021-05-25
BR112019015352A2 (pt) 2020-03-10
CA3051605A1 (en) 2018-08-02
PH12019501693A1 (en) 2020-06-15
AU2018211801B2 (en) 2021-07-08
KR102571911B1 (ko) 2023-08-28
ES2872923T3 (es) 2021-11-03
JP6605763B2 (ja) 2019-11-13
EP3575293A4 (en) 2019-12-04
IL268221A (en) 2019-09-26
US20190389837A1 (en) 2019-12-26
WO2018139527A1 (ja) 2018-08-02
EP3575293B1 (en) 2021-03-10
WO2018139527A9 (ja) 2018-09-20
TWI779007B (zh) 2022-10-01
KR20190111035A (ko) 2019-10-01
MY196680A (en) 2023-04-29
SG11201906819VA (en) 2019-08-27
DK3575293T3 (da) 2021-04-26
JPWO2018139527A1 (ja) 2019-06-27
TW201833099A (zh) 2018-09-16
RU2019123279A3 (pl) 2021-03-31
HUE054883T2 (hu) 2021-10-28
MX2019008787A (es) 2019-09-11

Similar Documents

Publication Publication Date Title
ZA202102356B (en) Sting agonistic compound
ZA201908367B (en) Molten salt reactor
PT3466934T (pt) Compostos de sulfonamida ou seus sais como inibidores da ribonucleótido-redutase para o tratamento de cancro
IL275415A (en) sGC fans
IL271399A (en) Methods for the preparation of heterocyclic 3,1-benzodioxole compounds
EP3426260A4 (en) FOR THE TREATMENT OF DISEASES USEFUL C-GLYCOSIDE COMPOUNDS
PL3575293T3 (pl) Sól etanosulfonianowa n-{5-[(6,7-dimetoksy-4-chinolinyl)oksy]- 2-pirydy-nylo}-2,5-diokso-1-fenylo-1,2,5,6,7,8-heksahydro-3-chinolinokarboksamidu
GB202200878D0 (en) Motion feedthrough
ZA201907272B (en) N-(4-pyridyl)nicotinamide compound or salt thereof
KR101983999B9 (ko) 용융염 전해 정련 장치
GB201705177D0 (en) Device to aid movement of substance from the eye
GB2566923B (en) Motion tracking
IL282731A (en) Organogulfonic compounds
HK1217918A1 (zh) 用於治療何杰金氏淋巴瘤的 -氰基- -二甲基環己- -烯- -基 -四甲基四氫- -吡喃- -基 吡啶- -基 -咪唑- -酰胺
GB201809460D0 (en) Salt form
GB201809458D0 (en) Salt form
IL253717A0 (en) Crystalline form of s-(4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl)6a,9a-difluoro-17a,-(furan-2-yl)carbonyloxy-11b-hydroxy-16a-methy1-3 -oxoandrosta-1,4-diene-17b-carbothioate
EP3256131A4 (en) 3,5-DIHYDROXYPENTANOATE ANALOGUES FOR BONE FORMATION
HUP1700542A2 (en) Nucleosides modified by 5'-linker
GB201717983D0 (en) Improvements to the operation of electromagnetic actuators
IL274084A (en) Comb for the treatment of dandruff
GB201704645D0 (en) Mammalian Trade-off-Weight"(mTOW)
GB201711901D0 (en) Salt
GB201711900D0 (en) Salt
GB201711899D0 (en) Salt